Charles River Laboratories International, Inc. — FY 2016 Form 10-K
Business context and reporting period. Charles River is a global early-stage contract research organization providing research models, discovery and safety-assessment services, and manufacturing-support products and services. The fiscal year ended December 31, 2016 and included 53 weeks, with the extra week in the fourth quarter; FY 2015 ended December 26, 2015. FY 2016 results include WIL Research from April, Blue Stream from June, and Agilux from September. The company reported three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 | Change |
|---|---|---|---|
| Revenue | $1,681.4 million | $1,363.3 million | +23.3% |
| Operating income | $237.4 million | $206.4 million | +15.0% |
| Operating margin | 14.1% | 15.1% | Down 1.0 percentage point |
| Income from continuing operations | $156.1 million | $152.0 million | +2.7% |
| Diluted EPS, continuing operations | $3.22 | $3.15 | +2.2% |
| Net cash from operating activities | $300.4 million | $288.2 million | +4.2% |
| Capital expenditures | $55.3 million | $63.3 million | −12.6% |
Revenue less cost of services and products, excluding intangible amortization, was $646.7 million, or approximately 38.5% of revenue, compared with approximately 39.0% in FY 2015. Net income attributable to common shareholders was $154.8 million, versus $149.3 million. Fourth-quarter revenue was $466.8 million versus $353.9 million, and diluted EPS was $0.93 versus $0.67.
Segment revenue: RMS $494.0 million (+5.0%); DSA $836.6 million (+36.7%); Manufacturing $350.8 million (+25.0%). Management attributed much of DSA growth to WIL Research and acquisitions; foreign exchange reduced consolidated revenue by $20.0 million, or 1.5%.
Cash, debt, and liquidity: Cash and equivalents were $117.6 million at year-end, broadly unchanged from $117.9 million. Debt and capital leases totaled approximately $1.21 billion, up from $846.0 million; approximate net debt was $1.09 billion. Current assets were $656.8 million and current liabilities $429.6 million. Operating cash flow less capital expenditures was approximately $245.1 million. The company stated that existing funds, operating cash flow, and financing access should be adequate for the foreseeable future. It complied with credit-facility covenants at year-end.
Material changes and management commentary
- Reported revenue increased substantially, led by acquired safety-assessment operations and stronger study volume, service mix, and pricing in legacy safety assessment. Acquisition contribution means reported growth should not be read as wholly organic; the filing does not provide a consolidated organic-growth rate.
- DSA revenue rose 36.7%, while its costs as a share of revenue increased to 68.4% from 66.5%, primarily reflecting WIL Research. RMS revenue grew 5.0% and its cost ratio improved; Manufacturing revenue grew 25.0% and its cost ratio also improved.
- Interest expense increased to $27.7 million from $15.1 million, reflecting higher average debt, interest rates and debt-modification costs. The effective tax rate rose to 30.0% from 22.2%, primarily due to nondeductible acquisition and restructuring costs and comparison with prior-year tax benefits.
- Acquisitions included WIL Research for $604.8 million, Blue Stream for $11.7 million, and Agilux for $64.9 million. Acquisition and asset purchases used $648.5 million of cash, net of cash acquired.
- Management reported robust manufacturing-support demand, stronger safety-assessment demand and utilization approaching optimal levels, with moderate price improvement. Demand for discovery services was strong among biotechnology clients but fluctuated among larger pharmaceutical clients; research-model demand improved modestly.
Outlook, risks, and unusual items
The filing contains no specific numerical FY 2017 revenue, earnings, or cash-flow guidance. Management expressed optimism about continued outsourcing and demand but noted that client research budgets, outsourcing levels, and project timing can change.
- Portfolio change after year-end: On February 10, 2017, the company sold the WIL Research contract development and manufacturing (CDMO) business for $75.0 million cash, subject to adjustments. It represented about 1% of FY 2016 revenue. The company was still evaluating the accounting impact and potential gain or loss.
- Contingency: The company recorded a $1.8 million estimated liability for excess billings on a small subset of government contracts and was cooperating with government authorities. The final settlement amount could change.
- Legal matter: A patent dispute with IDEXX was settled on February 6, 2017; the complaint and the company’s patent review proceeding were withdrawn.
- Restructuring and impairment: The company recorded a $9.4 million charge related to consolidating small DSA facilities, $8.5 million in workforce-reduction costs, and a $1.9 million impairment of certain DSA intangible assets. Goodwill impairment testing found no impairment.
- Key risks: Dependence on pharmaceutical and biotechnology R&D spending and outsourcing; intense competition and pricing pressure; acquisition integration and goodwill risk; animal-population contamination and regulatory compliance; foreign-exchange exposure; potential cyber or data-security breaches; contract cancellation and fixed-price cost overruns; and evolving animal-research methods and regulation.
- Debt is predominantly floating-rate; the filing estimates a 100-basis-point rate increase would add approximately $12.1 million to annual pretax interest expense. A 10% strengthening of the U.S. dollar was estimated to reduce annual revenue by $65.9 million and operating income by $2.8 million, all else equal.
Important facts for investors to verify
- Separate acquisition-driven growth from organic performance, particularly in DSA, and track safety-assessment utilization, pricing, and margins.
- Assess debt reduction and interest-rate sensitivity against acquisition integration, capital needs, and the scheduled 2021 credit-facility maturity.
- Review the final financial impact of the CDMO divestiture and whether the proceeds are deployed as management described.
- Monitor the resolution of the government-contract billing matter and any changes to the recorded estimate.
- Note that management and the auditor reported effective internal controls, but the FY 2016 assessment excluded the three businesses acquired during the year, representing 7.8% of assets and 11.1% of revenue.